Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2015-09-29 Major Shareholding Noti…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2015
Major Shareholding Notification Classification · 98% confidence The document is titled "Storaktionærmeddelelse" (Major Shareholder Announcement) and explicitly states that FMR LLC (Fidelity Management and Research) has reduced its indirect ownership stake in Genmab A/S to 9.95%, referencing Danish securities law (Værdipapirlovens paragraf 29). This type of filing specifically reports changes in significant share ownership levels, crossing ownership thresholds. This directly matches the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the announcement itself, not a larger report.
2015-09-29 English
Regulatory Filings 2015
Regulatory Filings
2015-09-25 Danish
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a specific corporate event: the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granting an accelerated assessment procedure for a marketing authorization application (MAA) for the drug daratumumab. This type of announcement, which communicates a regulatory milestone or corporate development to the market, is characteristic of a general regulatory filing or company news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a presentation (IP), and it is a formal announcement of a regulatory/business event, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). The document length (10,333 chars) is substantial, but its content is purely informational/developmental rather than a formal financial statement or a proxy solicitation.
2015-09-25 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and details a specific regulatory event: the US FDA granting Priority Review status for a supplemental Biologics License Application (sBLA) for the drug ofatumumab, setting a PDUFA date of January 21, 2016. This is a time-sensitive, material announcement regarding regulatory progress and clinical data, typical of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory action and clinical trial updates, rather than a full financial report (10-K, IR) or a general notice about a report being published (RPA), it fits best as an Earnings Release (ER) which often includes key operational and regulatory milestones, or RNS as a general regulatory announcement. Given the focus on a specific regulatory milestone and the structure of a press release, ER is a strong candidate, but RNS is the most accurate fallback for specific, non-financial regulatory news that isn't a formal report. However, in the context of biotech/pharma, major regulatory updates like this are often categorized under ER if they are the primary news driver for the period, or RNS if they are purely regulatory updates. Since this is a press release format announcing a specific regulatory decision (Priority Review), and it is not a full financial report, RNS (Regulatory Filings) is the most appropriate general category for this type of specific, non-financial regulatory news update that doesn't fit other specific codes like DIV or CAP. It is not a Call Transcript (CT) or Investor Presentation (IP). I will classify it as RNS as it is a general regulatory announcement.
2015-09-19 English
Legal Proceedings Report 2015
Legal Proceedings Report Classification · 99% confidence The document is titled 'Company Announcement' and details a specific regulatory event: the U.S. FDA granting Priority Review to a supplemental Biologics License Application (sBLA) for the drug ofatumumab. This is a material event concerning regulatory progress and clinical development, but it is not a comprehensive financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is a specific announcement about a regulatory milestone. Since it is a formal announcement of a significant corporate event that doesn't fit the specific financial report codes (10-K, IR, ER, MRQ), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, material regulatory update, or potentially a Legal/Regulatory update (LTR), but RNS is the broader fallback for non-standard announcements. Given the context of FDA action, RNS is the most appropriate general regulatory announcement code.
2015-09-19 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled "Genmab meddeler, at der er indsendt registreringsansøgning i Europa for daratumumab..." and is explicitly labeled as a "Selskabsmeddelelse" (Company Announcement). It announces a specific corporate event: the submission of a Marketing Authorization Application (MAA) to the EMA for a drug (daratumumab) and the resulting milestone payment. This type of announcement, detailing regulatory submissions, clinical trial updates, or partnership milestones, falls under the general category of corporate news or regulatory updates. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), it best fits the general Regulatory Filings (RNS) category, which serves as a fallback for significant, non-standard corporate news announcements that are not covered by other specific codes like DIV or CAP. The length (9826 chars) is substantial, but the content is purely an announcement of an action taken, not the regulatory document itself.
2015-09-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.